Preclinical News and Research

RSS

Domainex, has core intellectual property rights granted for Europe

Domainex Ltd (Domainex) today announced the grant of European Patent No.1442134 for its Combinatorial Domain Hunting (CDH) Technology.

From Domainex 10 Sep 2008

Eastern Virginia Medical School receives $100 million grant from USAID for microbicide research

Eastern Virginia Medical School on Monday announced that it has received a $100 million grant from USAID for microbicide research through its CONRAD program, the Virginian-Pilot reports.

10 Sep 2008

Coated lenses set to reduce 'post-op' infections for cataract patients

Research presented at the British Pharmaceutical Conference (BPC) in Manchester reveals that coating an artificial lens with antibiotics could significantly reduce the risk of post-operative infection, and even blindness, for cataract patients.

7 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Vimpat (lacosamide) approved in Europe

UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.

3 Sep 2008

FDA authorizes INDA for recombinant human C1 inhibitor in kidney transplantation

Biotech company Pharming Group NV has announced that the US Food and Drug Administration (FDA) has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection (AMR) in kidney transplantation. Dr. Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with rhC1INH under an Investigator IND from the FDA.

3 Sep 2008

Nature inspires new highly specific drugs and organic products

The best place to seek novel compounds for pharmaceutical drugs, alternative energy sources, and a host of industrial applications, is within natural systems that have evolved over millions of years.

2 Sep 2008

MorphoSys announces publication of first MOR103 data

MorphoSys AG announced today the publication of a first data package for its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF, in the journal "Molecular Immunology".

2 Sep 2008

New molecular imaging techniques aim at detection of earliest steps of disease development

An emerging discipline of noninvasive cardiac imaging, molecular imaging, has evolved constantly in the last few years and is increasingly being translated from the preclinical to the clinical level.

31 Aug 2008

FDA grants IND for Davanat to treat breast cancer patient

Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.

28 Aug 2008

Genzyme, Medicines for Malaria Venture, Advinus collaborate on malaria initiative

The Cambridge, Mass.-based biotechnology firm Genzyme on Monday announced it will collaborate with the not-for-profit group Medicines for Malaria Venture and the Indian pharmaceutical company Advinus Therapeutics to develop new malaria treatments, the Boston Business Journal reports.

26 Aug 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

Galapagos acquires structure-based drug discovery from Sareum

Galapagos NV and Sareum Holdings plc has announced today that Galapagos has acquired Sareum's assets in drug discovery services, for a total cash consideration of EUR 695,000 (£553,000). These assets will position Galapagos' service division BioFocus DPI strongly in the growing field of structure-based drug discovery.

26 Aug 2008

Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer?

Prof. Eliezer Flescher of The Sackler Faculty of Medicine, Tel Aviv University thinks so. He and his colleagues have developed an anti-cancer drug based on a decade of research into the commercial applications of the compound Jasmonate, a synthetic compound derived from the flower itself.

25 Aug 2008

Eli Lilly acquires SGX Pharmaceuticals

Eli Lilly and Company has announced that it has completed the acquisition of SGX Pharmaceuticals, Inc. (Public, NASDAQ:SGXP), a San Diego-based biotechnology company focused on drug discovery and development in the area of oncology.

20 Aug 2008

Addiction drug Vigabatrin proves successful in animal weight loss study

Vigabatrin, a medication proposed as a potential treatment for drug addiction by scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, also leads to rapid weight loss and reduced food intake according to a new animal study from the same research group.

20 Aug 2008

Isis Pharmaceuticals trials C-reactive protein drug

Isis Pharmaceuticals, Inc. announced today it has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive protein (CRP). CRP levels are frequently elevated in patients with a variety of diseases including cardiovascular disease, Crohn's disease, rheumatoid arthritis and end-stage renal disease.

13 Aug 2008

NanoBio vaccine for hepatitis B shows promise

Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.

13 Aug 2008

Massage speeds recovery after a sports injury

Researchers testing the long-held theory that therapeutic massage can speed recovery after a sports injury have found early scientific evidence of the healing effects of massage.

12 Aug 2008

Designer RNA fights high cholesterol, medical researchers find

Small, specially designed bits of ribonucleic acid (RNA) can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests, according to a new study by researchers at UT Southwestern Medical Center in collaboration with Alnylam Pharmaceuticals and the Massachusetts Institute of Technology.

11 Aug 2008